What makes UpToDate so powerful?

  • over 11000 topics
  • 22 specialties
  • 5,700 physician authors
  • evidence-based recommendations
See more sample topics
Find Patient Print
0 Find synonyms

Find synonyms Find exact match

Barrett's esophagus: Treatment of high-grade dysplasia or early cancer with endoscopic resection
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
Barrett's esophagus: Treatment of high-grade dysplasia or early cancer with endoscopic resection
View in Chinese
All topics are updated as new evidence becomes available and our peer review process is complete.
Literature review current through: Nov 2017. | This topic last updated: Feb 22, 2017.

INTRODUCTION — Barrett's esophagus (BE) is thought to be a complication of longstanding gastroesophageal reflux, resulting in the replacement of the normal squamous lining of the distal esophagus by columnar, epithelium-containing, specialized intestinal metaplasia. (See "Barrett's esophagus: Epidemiology, clinical manifestations, and diagnosis".)

Endoscopic surveillance is recommended for patients with BE because of its malignant potential in the hope of detecting dysplasia before it progresses to adenocarcinoma. Esophagectomy has traditionally been recommended for patients found to have high-grade dysplasia or early cancer. (See "Barrett's esophagus: Surveillance and management".)

Endoscopic therapy has been proven to be a safe, effective, and less invasive alternative to surgery for treating such patients.

Endoscopic resection (ER) is an endoscopic approach in which the neoplastic epithelium is excised, thus allowing for a definitive histologic diagnosis while also potentially being curative. ER has been applied not only to BE with high-grade dysplasia but also to early cancer in which the risk of lymph node involvement or hematogenous dissemination is low enough to justify a relatively conservative approach compared with esophagectomy [1-8].

Several studies have demonstrated that ER is safe and effective for complete resection of superficial lesions and offers the advantage of histopathologic verification [9-12].

Prior ER does not impair subsequent ablative therapy (eg, photodynamic therapy, argon plasma coagulation, or radiofrequency ablation) for treatment of larger areas of residual Barrett's mucosa. Ablative therapy alone provides no specimen for histopathologic evaluation.

ER is considered the cornerstone of endoscopic management, and ablative techniques are mainly used as an adjunct to ER [13].

The experience with ER in patients with BE who have high-grade dysplasia or early cancer is discussed here. Photodynamic therapy, radiofrequency ablation, a general approach to BE, and other treatment options for superficial esophageal cancer are presented separately. (See "Barrett's esophagus: Treatment with photodynamic therapy" and "Barrett's esophagus: Treatment with radiofrequency ablation" and "Barrett's esophagus: Surveillance and management" and "Management of superficial esophageal cancer".)

EVALUATION FOR ELIGIBILITY — There are three major considerations in the evaluation of patients with Barrett's esophagus (BE) who have high-grade dysplasia (HGD) or early cancer: histopathologic evaluation, the endoscopic work-up, and staging of the lesions.

Histopathologic evaluation — Esophageal neoplasia is usually classified according to the internationally accepted Vienna classification [14]. The Vienna classification is based upon the histopathologic evaluation of endoscopically acquired biopsies:

Category 1: No dysplasia

Category 2: Indefinite for dysplasia

Category 3: Low-grade intraepithelial neoplasia (low-grade adenoma/dysplasia)

Category 4: High-grade intraepithelial neoplasia (high-grade adenoma/dysplasia, noninvasive carcinoma or suspicion of invasive carcinoma)

Category 5: Invasive epithelial neoplasia (intramucosal carcinoma, submucosal carcinoma, or beyond)

The distinction between categories 4 and 5 can be difficult since it depends in part upon the size, location, depth, and number of biopsies. In category 4, there is no obvious invasion beyond the epithelial basal membrane. Category 5 is subdivided based upon whether there is invasion into the lamina propria or muscularis mucosa (category 5.1, also referred to as intramucosal cancer) or into the submucosa (category 5.2, also referred to as submucosal cancer).

Another problem with the diagnosis of dysplasia in Barrett's epithelium is the interobserver reliability among pathologists. As a result, it is helpful to achieve a consensus (ie, from more than one pathologist) in categorizing such specimens. A consensus diagnosis has better predictive value regarding prognosis and may revise the original diagnosis, which can have implications for subsequent management [15,16]. These observations underlie the recommendation that a second, experienced pathologist should confirm the diagnosis of HGD. (See "Barrett's esophagus: Surveillance and management".)

Endoscopic evaluation — Patients diagnosed with HGD or early cancer in BE should undergo an endoscopic work-up in a center with expertise in evaluating such patients. The reasons for this are threefold:

Evaluation at a specialized center helps assure that a second, experienced endoscopist can confirm the findings of the initial endoscopy, making a false positive diagnosis less likely. Up to 40 percent of patients who are diagnosed with HGD have no dysplasia at follow-up endoscopies [17]. If the diagnosis of HGD is confirmed in biopsies obtained on a separate occasion, the chance of over-diagnosis and unnecessary treatment should be reduced.

Evaluation at a specialized center permits detection of synchronous lesions elsewhere in the BE that might otherwise be left untreated. This is especially important if endoscopic therapy is being considered.

Specialized centers often have integrated expertise in gastrointestinal pathology, endoscopy, and surgery, and the experience to offer advanced endoscopic techniques such as ER.

Early neoplastic lesions in BE are often difficult to detect with standard video endoscopy. Although a number of techniques have been proposed to increase the accuracy of endoscopic imaging (such as chromoendoscopy, magnification endoscopy, and optical coherence tomography), none is used routinely in clinical practice. (See "Chromoendoscopy" and "Magnification endoscopy" and "Barrett's esophagus: Evaluation with narrow band imaging" and "Barrett's esophagus: Evaluation with autofluorescence endoscopy" and "Confocal laser endomicroscopy and endocytoscopy" and "Optical coherence tomography in the gastrointestinal tract".)

Three general rules should be followed in the endoscopic evaluation of patients being considered for ER:

Use the best endoscope available

Have a vigilant eye for detecting mucosal abnormalities

Use a systematic, meticulous approach

Use the best endoscope available — High-resolution endoscopy may have higher sensitivity for the detection of early BE neoplasia compared with standard video endoscopy systems [18,19]. Because early BE neoplasia often presents as flat lesions with only subtle mucosal abnormalities, most experts agree that high-resolution endoscopy is the preferred method for the endoscopic evaluation of BE.

Have a vigilant eye — Up to 80 percent of patients referred for evaluation of HGD or early cancer without visible abnormalities will have at least one visible abnormality detected in their BE upon endoscopic inspection by expert endoscopists [18,20]. Although early BE neoplasia generally presents as subtle, flat lesions that can be difficult to detect, most state-of-the-art endoscopes are capable of revealing these abnormalities when viewed by highly experienced endoscopists. Thus, familiarity with the endoscopic appearance of early Barrett's neoplasia is essential for its diagnosis.

Perform a systematic endoscopic inspection — The detection of gross mucosal abnormalities such as elevations, ulcerations, and nodularities is relatively easy. By comparison, the detection of subtle abnormalities requires a more careful and thorough inspection, making a systematic approach imperative.

After intubation of the esophagus, the esophagus should be carefully cleaned to remove any mucus or saliva. Simple water flushes usually are sufficient, but spraying acetylcysteine (1 percent) can be helpful if there is excessive or viscous mucus. It is important to suction all gastric secretions to prevent reflux into the esophagus that could interfere with inspection.

The endoscope should be gradually withdrawn to examine the BE segment for mucosal irregularities and to describe the extent of BE. One system for doing so uses the validated Prague C & M criteria, which assess the circumferential and maximum extent of the visualized BE segment [21]. After initial inspection, the inflated esophagus should be gradually deflated to reveal any irregularities that may have flattened during inflation, making them more difficult to see. Special attention should be paid to the area between 12 and 6 o'clock in the endoscopic view, where the majority of neoplastic lesions are found [22]. In addition, if a hiatal hernia is present, it is important to inspect the transition of the BE into the hiatal hernia in the retroflexed position since abnormalities in this area are easily overlooked in the antegrade view.

The Seattle biopsy protocol is recommended for mapping BE with HGD [23]. Targeted biopsies are obtained from all visible abnormalities, and random four-quadrant biopsies are taken every 1 cm starting from the top of the gastric folds up to the most proximal extent of the BE (squamocolumnar junction).

The importance of random biopsies every 1 cm rather than every 2 cm was demonstrated in a study in 45 patients with BE and HGD [23]. The authors calculated that using a standard protocol would have missed 50 percent of cancers that were detected by the 1 cm protocol.

Based upon the above observations, inspection and classification of all visible lesions should be followed by biopsies from each visible abnormality and then random four-quadrant biopsies. The biopsies should always start distally, working upwards to minimize bleeding that obscures visualization. We follow the rule "look longer, biopsy less" since, in our experience, the diagnosis of HGD or early cancer can be made in 80 to 90 percent of patients with these lesions by targeted biopsies after a thorough inspection [24]. However, random four-quadrant biopsies are still required since 10 to 20 percent of lesions are missed with targeted biopsies alone.

In addition, the American Society for Gastrointestinal Endoscopy (ASGE) has issued guidelines that recommend ER for the treatment and staging of nodular BE and suspected intramucosal adenocarcinoma [25].

Endoscopic resection as staging procedure — We consider ER to be both a reasonable treatment option and also the final step in the diagnostic work-up of patients with HGD or early cancer in BE [26-28]. In one study, interobserver agreement about the presence of neoplasia was significantly better on ER specimens than biopsy specimens [27]. This approach is consistent with 2013 guidelines from the ASGE that recommend ER for the treatment and staging of nodular BE and suspected intramucosal adenocarcinoma [25]. If the endoscopic appearance of the lesion does not raise suspicion for deep submucosal infiltration, the lesion may be removed by ER.

The most important predictor of lymph node metastasis is the penetration depth of the tumor [29]. ER of the most suspicious area in the Barrett's segment, followed by histopathologic evaluation of the resected specimen, permits assessment of infiltration depth and estimation of the risk for local lymph node metastasis.

Other staging procedures — Among patients diagnosed with HGD or early cancer, other imaging techniques could be considered to evaluate tumor infiltration depth, local lymph node status, and metastatic spread. Endoscopic ultrasonography and computerized tomography (CT) scan are the most widely used techniques.

Endoscopic ultrasound — Endoscopic ultrasound (EUS) is the most accurate technique for locoregional staging of esophageal cancer. However, EUS is less reliable for T- and N-staging in patients with HGD and early cancer than in patients with more advanced esophageal cancer. In addition, accuracy is influenced by the experience of the endosonographer [30,31]. (See "Endoscopic ultrasound in esophageal carcinoma" and "Diagnosis and staging of esophageal cancer".)

High-frequency miniprobes may improve the accuracy of T-staging compared with standard EUS, but the accuracy of N-staging appears to be inferior to standard EUS because, while it is higher resolution, the visualization is more superficial [30]. (See "High-frequency catheter endoscopic ultrasonography".)

T-staging (depth of invasion) – Differentiating mucosal lesions from lesions infiltrating into the submucosa is much more difficult in BE than in the squamous esophagus for the following reasons [32,33]:

The crypts and villi present in BE are more heterogeneous than the layered architecture of squamous epithelium.

BE neoplasia can be associated with significant inflammatory changes and the presence of double muscularis mucosae.

Most Barrett's lesions are located in the distal esophagus close to the cardia, where EUS interpretation is known to be difficult.

There appears to be limited added value of EUS for determining T-staging once tumor depth has been estimated by endoscopic inspection of the lesion of interest by an expert endoscopist [32,34].

N-staging (nodal status) – In the work-up and staging of patients with early neoplasia, N-staging is of crucial importance since positive lymph nodes will exclude patients from endoscopic treatment. EUS has a high negative predictive value (>95 percent) for the absence of tumor infiltration into the deeper wall layers and local lymph nodes [30]. Ultimately, however, the best method for assessment of the risk of lymph node involvement is not EUS, but assessment of the depth of infiltration of the lesion after endoscopic resection.

CT scanning — The value of CT scanning lies mainly in the detection of distant metastases. The risk for distant metastases is very low in patients with HGD or early cancer who show no signs of deep submucosal infiltration or suspicious lymph nodes on EUS. Thus, the value of CT is limited in such patients.

Other radiographic modalities — Other imaging techniques, such as positron emission tomography scanning and magnetic resonance imaging, do not have a role in the work-up of patients with esophageal HGD or early cancer.

ENDOSCOPIC RESECTION TECHNIQUES — A variety of endoscopic resection (ER) techniques have been described for the esophagus, primarily for esophageal squamous neoplasia.

Established techniques

Endoscopic resection-cap — The ER-cap technique is performed after submucosal lifting (figure 1 and picture 1) [35,36]. The target lesion is first lifted by injection of a fluid, which may be saline or diluted epinephrine (1:100,000), into the submucosal layer. Subsequently, a transparent cap is attached to the endoscope. The cap has a distal ridge that allows positioning of a crescent-shaped ER-snare. The lesion is sucked into the cap, thus creating a pseudopolyp that is immediately captured by forcefully closing the pre-positioned ER-snare. The lesion is then removed using electrocoagulation. (See "Overview of endoscopic resection of gastrointestinal tumors".)

ER-caps are available with different diameters and have either a straight or an oblique shape. The largest en bloc resections are achieved with a large caliber flexible cap that, despite its large outer diameter of 18 mm, can be relatively easily introduced into the esophagus due to its flexibility. Using this technique, lesions with a diameter of more than 2 cm can be removed en bloc.

Multiband mucosectomy — Multiband mucosectomy (MBM) uses a modified variceal band ligator with six bands and a handle that allows passage of a hexagonal snare alongside the releasing wires for the bands. Suction is used to draw the lesion into the cap, a rubber band is deployed, and a polypoid lesion is created. The "polyp" can then be removed using a snare that is inserted through the biopsy channel. Multiple specimens can be removed during the procedure using this device (picture 2).

This MBM technique has several advantages:

As a modification of the "suck-band-and-ligate" technique, it does not require submucosal injection as with the ER-cap technique. The reason is that the esophageal muscle layer will immediately retract when captured within a rubber band, whereas with the standard ER-cap technique it will remain captured in the forcefully closed ER-snare.

Multiple resections can be performed with the same snare.

Pre-looping the ER-snare in the ridge of the cap is not necessary.

MBM does not require withdrawal of the endoscope between resections as is needed with the "conventional" suck-band-and-ligate technique. Since the instrument holds six rubber bands, up to six consecutive resections can be performed. This reduces the time and cost required for the procedure while also reducing patient discomfort.

A prospective registration of 243 MBM procedures in patients with Barrett's esophagus (BE) demonstrated that the technique is safe and effective. Complications occurring during the procedure (acute complications) were observed in 3 percent. Bleeding was the only acute complication, and in all cases it was managed endoscopically. No perforations occurred. Complications within 30 days of the procedure (early complications) included delayed bleeding (2 percent of procedures) that was managed endoscopically and stenosis (48 percent). Endoscopic complete resection was achieved in 91 percent of focal lesions [36].

In a case control study, 80 MBM procedures were compared with 86 ER-cap procedures [37]. The study showed that MBM was safe and effective for widespread ER in BE. MBM appeared to be quicker than ER-cap, but the specimens removed with MBM were significantly smaller than with the ER-cap technique.

Following this case-control study, a multicenter randomized controlled trial was initiated to compare the ER-cap technique and MBM for piecemeal resection of early neoplasia in BE [38]. The trial included 84 patients (42 assigned to MBM and 42 to ER-cap) and found that procedure times and costs were significantly less with MBM versus ER-cap (34 versus 50 minutes and 240 versus 322 euro, respectively). MBM resulted in smaller specimens than ER-cap (18 versus 20 mm in longest dimension). There were no significant differences in maximum specimen thickness or the amount of submucosa resected. There were three perforations in the ER-cap group and one perforation in the MBM group. The perforations in the ER-cap group were treated endoscopically, whereas the perforation in the MBM group required surgical repair because of periesophageal scarring that prevented endoscopic closure.

MBM appears to be safe and fast for widespread ER in BE. Time and costs appear to be saved compared with ER-cap since submucosal lifting is not required and a single snare can be used for all resections. MBM does not appear to be associated with more complications than ER-cap despite the lack of submucosal lifting. MBM results in significantly smaller-sized resections, but the clinical relevance of this finding may be questioned since there was no significant difference in the depth of resection between the two techniques.

Endoscopic submucosal dissection — Endoscopists have used specially designed needle knives for en bloc dissection of large esophageal lesions, a technique known as endoscopic submucosal dissection (ESD) [39-43]. The main advantage of ESD is that it allows for en bloc resection of lesions, but it is associated with a longer procedure time and a higher risk of complications compared with endoscopic mucosal resection (EMR). A randomized trial comparing ESD (n = 20) with EMR (n = 20) for patients with BE with high-grade dysplasia (HGD) or early adenocarcinoma demonstrated a higher radical resection rate after ESD (10 of 17 versus 2 of 17; p = 0.01) [44]. However, there appeared to be few clinical benefits from the higher radical resection rate; there was no difference in complete remission from neoplasia at three months (15 of 16 for ESD versus 16 of 17 for EMR) and, during a mean follow-up period of 23 months, recurrent early adenocarcinoma was observed in one patient in the ESD group [44]. In addition, ESD was associated with a perforation in two patients and a significantly longer procedure time (mean 54 versus 22 minutes; p = 0.0002).

The European Society of Gastrointestinal Endoscopy guidelines recommend piecemeal EMR over ESD in most cases of Barrett's early neoplasia [45]. We reserve ESD for patients with a strong suspicion of submucosal invasion and for the resection of lesions with a large intraluminal component prohibiting a cap-based resection (ie, the intraluminal part of the lesion would fill the cap upon suctioning, and resection of the basal mucosal layers might be incomplete despite the absence of deep submucosal invasion). We perform ESD for less than 10 percent of all early Barrett's neoplasia cases. (See "Overview of endoscopic resection of gastrointestinal tumors", section on 'Endoscopic submucosal dissection'.)

Hybrid-Argon Plasma Coagulation — An application of argon plasma coagulation that combines submucosal saline lift with diffuse tissue thermal ablation has been used for the ablation of Barrett’s esophagus [46,47]. (See "Argon plasma coagulation in the management of gastrointestinal hemorrhage", section on 'Endoscopic mucosal resection or ablation'.)

Learning curve — ER is a technically demanding procedure that requires specific endoscopic expertise, both to resect lesions in a safe and effective manner, and to manage complications that may arise during ER procedures. (See 'Complications' below.)

However, studies on the learning curve of ER are limited, and most have assessed the learning curve of the ESD technique only. The majority of studies come from Asia and show that the experience and level of training in ESD of the endoscopist are associated with an increase in complete ER rate and decreases in perforation rate and procedure time [48-50].

A study from the Netherlands has evaluated the implementation of a structured training program for esophageal ER. The training program of six teams (consisting of an endoscopist, an endoscopy nurse, and a pathologist) is aimed at controlled implementation and centralization of ER procedures in the Netherlands. Training resulted in a high success rate of complete ER of lesions, although the observed perforation rate of 5 percent suggested that performing 20 ER procedures is insufficient to reach the peak of the learning curve in ER for a single endoscopist [51].

ER should only be performed by trained endoscopists with experience in screening, imaging, and treatment of patients with early Barrett's neoplasia. Integrated expertise in surgery and histopathology at these expert centers is preferable. A minimum case load per year may be recommended.

ACID SUPPRESSION FOLLOWING ENDOSCOPIC RESECTION — Patients should be treated with adequate acid suppression to allow the ER wounds to heal with neosquamous epithelium and probably also to reduce local scarring. Most centers treat patients with high-dose proton pump inhibitors (we use esomeprazole 40 mg twice daily).

The wounds generally heal in three to six weeks depending upon the size of the resected area. No studies have evaluated the mucosal regenerative pattern after ER. In our experience, healing proceeds from proximal to distal with regeneration starting from the edges.

PATHOLOGIC ASSESSMENT — Interpreting endoscopic resection (ER) specimens of Barrett's neoplasia may be more difficult than specimens obtained from squamous lesions. The tissue architecture with crypts and villi differs from the layered architecture in squamous mucosa, making it more difficult to discern a clear transition between wall layers. This problem is further increased by the presence of a double muscularis mucosae in many patients with Barrett's esophagus (BE) [52]. Because the deeper muscle layer represents the true muscularis mucosae, lesions infiltrating through the superficial muscularis mucosae should not be considered as submucosal invading cancers.

Many early lesions in BE are associated with severe inflammation that is due to the accompanying reflux disease and may hamper histological assessment. Similarly, because ER involves the use of electrocoagulation, the deep and especially the lateral resection margins may have coagulation artifacts, complicating histologic evaluation compared with surgical resection specimens [53].

The ability to treat early cancer with ER underscores the important nuances of histopathologic assessment. However, making important distinctions between high-grade dysplasia (HGD) and invasive cancer (and its depth of invasion) may not be straightforward. In an illustrative report, the interobserver reliability for distinguishing BE with HGD from intramucosal cancer in surgical specimens was poor (kappa statistic 0.42) [54]. It was somewhat better for distinguishing intramucosal and submucosal cancer (kappa statistic of 0.71). Currently, the distinction between HGD and mucosal cancer is not considered clinically relevant. The two conditions are difficult to distinguish histologically, and both carry a virtually absent risk of local lymph node metastases. For clinical decision-making, the distinction between mucosal cancer and submucosal cancer is much more relevant.

Pathologic subclassification — The terminology and classification of early esophageal cancers have evolved and are outlined in the 2010 tumor node metastasis (TNM) staging system of the combined American Joint Committee on Cancer (AJCC)/Union for international Cancer Control (UICC) [55].

Early esophageal cancers are those that are classified as Tis (HGD, which includes all noninvasive neoplastic epithelial that was formerly called carcinoma in situ) or T1 tumors. T1 tumors are further split into T1a and T1b subcategories, depending upon the depth of invasion (table 1). However, this classification by itself is inadequate to distinguish differences in lymph node involvement among T1a and T1b esophageal cancers. (See "Diagnosis and staging of esophageal cancer", section on 'TNM staging criteria'.)

A more comprehensive subclassification scheme has been proposed for early esophageal cancers and is useful for determining prognosis and selecting treatment (figure 2) [56]. According to this classification, mucosal tumors are divided into three types based upon the depth of invasion:

M1 – Limited to the epithelial layer

M2 – Invades the lamina propria

M3 – Invades into but not through the muscularis mucosa

M1 tumors correspond to the Tis stage in the AJCC stage definition, while both M2 and M3 tumors would be considered T1a lesions.

Tumors invading the submucosa are subclassified as follows [56]:

SM1 – Penetrates the shallowest one-third of the submucosa (<500 microns)

SM2 – Penetrates into the intermediate one-third of the submucosa

SM3 – Penetrates the deepest one-third of the submucosa

All of these subcategories would be considered T1b disease according to the AJCC stage definitions [54].

For Barrett's neoplasia, ER is considered appropriate therapy for lesions limited to the superficial mucosal layers (M1 and M2 tumors) because these tumors have low rates of lymph node metastasis (<3 percent). There is less consensus, however, with regard to lesions that extend to the muscularis mucosa (M3 tumors), yet most centers consider this an accepted indication for endoscopic treatment of early Barrett's neoplasia, whereas for squamous neoplasia M3 lesions are a relative indication.

Esophagectomy is generally preferred for lesions that invade the submucosa (SM1, SM2, and SM3 tumors) given the significantly higher rates of lymph node metastasis associated with these lesions (table 2). Studies have suggested that ER may be appropriate for lesions that penetrate into the superficial submucosal (SM1 tumors with submucosal penetration <500 microns). The reason ER may be an option is that these lesions may have a low risk of positive lymph nodes, provided that they do not show poorly differentiated cancer or lymphovascular invasion [57,58]. Guidelines from 2012 therefore advise a nonsurgical approach for such low-risk SM1 tumors [13].

The above considerations underscore the importance of specialized referral centers where expert pathologists are available [11,16]. This topic is discussed in detail elsewhere. (See "Management of superficial esophageal cancer".)

EFFICACY — An understanding of the efficacy of endoscopic resection (ER) for management of high-grade dysplasia (HGD) or early cancer in Barrett's esophagus (BE) is evolving. The available evidence suggests that ER for these conditions has an initial success rate comparable to surgical treatment, but with fewer complications [9,12,59-67].

The rate of complete remission (ie, successful removal of the HGD or early cancer with ER) is variable, ranging from 59 to 99 percent in different studies [9,12,59-64,66-72]. In a systematic review that included 11 studies of patients with BE who underwent endoscopic mucosal resection, complete eradication of HGD or early cancer was achieved in 95 percent of patients, and complete eradication of all Barrett's mucosa was achieved in 89 percent [73]. Higher degrees of success are seen in patients with lower risk lesions, which are defined as macroscopic types I (protruded type), IIa (flat, elevated type), IIb (flat type), and IIc (flat, depressed type); a lesion diameter up to 20 mm that is limited to the mucosa; and histologically well- to moderately well-differentiated tumors.

Recurrence of carcinoma or the development of metachronous malignancies has been described in 6 to 30 percent of patients [9,12,59-63,65,66,69,70].

Multiple factors have been associated with recurrence [12,60,63,69,70,74]:

Larger lesion diameter

Long-segment BE

Removal of the lesion with piecemeal resection

Failure to perform adjunctive ablative therapy (photodynamic therapy, argon plasma coagulation, or radiofrequency ablation)

Presence of multifocal neoplasia

An elapsed time of more than 10 months prior to achieving complete remission

The presence of residual dysplasia

In most cases, recurrences can be successfully managed endoscopically [70].

One of the largest studies to look at the efficacy of ER for patients with early adenocarcinoma of the esophagus included 1000 patients who were followed for a mean of 56.6 months [70]. Complete remission was achieved in 96 percent of patients. Recurrent or metachronous lesions developed in 140 patients (15 percent) and were successfully treated endoscopically in 115 (82 percent of those with recurrence or metachronous lesions). Overall, the long-term complete remission rate was 94 percent.

The ideal candidate for ER has a solitary, small (ie, <2 cm diameter), flat-type lesion (usually a combination of types IIa, IIb, and IIc) that is limited to the mucosa. Histopathologic differentiation may be less important for most cases since the vast majority of these early lesions will be classified as HGD or well-differentiated cancers [11]. Tumors that are poorly differentiated or undifferentiated are associated with adverse outcomes in studies using univariate analysis, but these studies usually include patients with more advanced lesions [11].

In multivariate analyses, tumor differentiation has not been identified as an independent risk factor for lymph node metastasis or tumor recurrence [29]. This finding may be related to the fact that most undifferentiated tumors have already invaded the submucosa at the time of diagnosis [11]. However, reliable data on the relevance of histopathologic differentiation are sparse, especially given the small number of early, undifferentiated lesions in the available studies.

Because of the risk for recurrence, patients treated with ER require regular endoscopic follow-up to detect recurrent lesions. In most studies, patients are followed every three months during the first year and annually thereafter. Alternatively, the residual Barrett segment could be treated endoscopically. (See 'Endoscopic resection as part of endoscopic therapy' below and "Barrett's esophagus: Treatment with radiofrequency ablation" and "Barrett's esophagus: Treatment with photodynamic therapy".)

ENDOSCOPIC RESECTION AS PART OF ENDOSCOPIC THERAPY — An important drawback of endoscopic resection (ER) monotherapy for high-grade dysplasia (HGD) or early cancer (EC) in Barrett's esophagus (BE) is the high recurrence rate of 30 percent within five years during follow-up; therefore, eradication of the residual Barrett's mucosa should be recommended.

Endoscopic ablative therapy with radiofrequency ablation (RFA) or photodynamic therapy (PDT) allows treatment of the whole Barrett's segment in one session, which may permit treatment of larger areas and/or may be associated with a lower recurrence rate. Studies of RFA have reported impressive success rates when used in combination with ER for removal of visible abnormalities, both in the short and long term [75]. PDT has been investigated as monotherapy for HGD and EC in BE as well as an adjuvant treatment after ER; however, serious complications such as stricture occurred frequently, and 15 percent of patients who received PDT ultimately developed esophageal cancer. (See "Barrett's esophagus: Treatment with radiofrequency ablation" and "Barrett's esophagus: Treatment with photodynamic therapy".)

Stepwise endoscopic mucosal resection — Complete ER of the whole Barrett's segment (picture 3) may also be used as endoscopic therapy. This so-called stepwise radical endoscopic resection (SRER) technique offers the potential to remove the entire area of dysplastic and metaplastic tissue and has several advantages over ablative therapy.

It allows complete removal of the whole mucosa at risk for malignant progression.

It provides tissue samples for optimal histopathologic diagnosis.

It may reduce the likelihood of persistent and/or induced genetic abnormalities that are associated with the progression of BE to adenocarcinoma. (See "Barrett's esophagus: Pathogenesis and malignant transformation".)

Several series have demonstrated the feasibility and safety in experienced hands of ER of the entire Barrett's segment, even in patients with a long segment of BE [68,76]. As examples:

In a single-center United States series, 107 patients with HGD or EC in BE were treated with ER to remove the BE segment, either in a radical approach (single session) or in multiple treatment sessions. In a per-protocol analysis (eg, excluding patients who underwent surgery after ER or discontinued treatment for other reasons) 79 of 80 patients (99 percent) were treated successfully. Durability data were available for 74 patients who were followed for a median of 33 months; 74 of 74 patients (100 percent) had complete remission of HGD or EC, and 53 of 74 patients (72 percent) had complete remission from intestinal metaplasia [71].

In the largest multicenter series reported thus far, 169 patients with HGD or EC in BE up to 5 cm were treated with SRER to remove all neoplasia and Barrett's mucosa [77]. According to an intention-to-treat analysis, complete eradication of all neoplasia and all intestinal metaplasia by the end of the treatment phase was reached in 98 and 85 percent of patients, respectively. One patient had progression of neoplasia during treatment and died of metastasized adenocarcinoma (0.6 percent). After a median follow-up of 32 months (interquartile range 19 to 49 months), complete eradication of neoplasia and intestinal metaplasia was sustained in 95 and 81 percent of patients, respectively. Acute, severe complications occurred in 1.2 percent of patients, and 50 percent of patients developed symptomatic stenosis.

Focal endoscopic mucosal resection followed by radiofrequency ablation (RFA) — A multimodal approach using a combination of focal endoscopic resection and RFA for the treatment of HGD and EC in BE has been studied.

A systematic review of mostly observational studies analyzed outcomes in patients with HGD and/or EC in BE who underwent either SRER or focal ER followed by RFA [78]. Both interventions resulted in similar eradication rates of both neoplasia and intestinal metaplasia. Complications were more common in the SRER group: strictures (33.5 versus 10.2 percent; OR 4.7; 95% CI, 1.6-13.6), perforation (7.5 versus 1.1 percent, OR 7.0, 95% CI, 1.6-31.3) and bleeding (1.3 versus 0.2 percent, OR 6.9, 95% CI 2.2-21.6) compared with the focal ER and RFA group.

In the only randomized trial to date in which SRER was compared with focal ER followed by RFA, 47 patients were included who had HGD or EC in BE up to 5 cm. Twenty-five patients received SRER, and 22 patients received ER plus RFA. Complete eradication of all neoplasia (CE-neo) and all intestinal metaplasia (CE-IM) at the end of the treatment phase was similar in both groups (CE-neo 100 versus 96 percent, and CE-IM 92 versus 96 percent, respectively). The stenosis rate was higher in the SRER group than in the ER plus RFA group (88 versus 14 percent), which resulted in significantly more therapeutic sessions in the SRER group (six versus three procedures), mainly due to dilations. After a median follow-up of 24 months (interquartile range 18 to 29 months), a single patient in the SRER group had a recurrent cancer at the neosquamocolumnar junction, which could be removed with ER [79].

The role of the SRER technique seems limited to select patients in the treatment of HGD or EC in BE. Although the SRER technique is equally effective and has potential advantages over ablative therapy, the studies indicate that SRER is associated with a higher rate of stenosis than ER plus RFA. We would therefore advise to use the SRER technique only for patients with more extensive lesions in BE up to 5 cm [79].

COMPLICATIONS — Serious complications with the endoscopic resection (ER) techniques described above are rare, though complications such as stricture formation are common if large areas of Barrett's mucosa are resected [9,68,80,81]. Studies have shown that the risk of complications increases with piecemeal resection and the degree of involvement of the mucosa [80,82]:

Bleeding occurs in 0 to 46 percent of cases (depending in part on how it is defined) and can usually be managed easily with endoscopic methods [9,61,63,64,70,81,83]. We suggest that immediate bleeding be regarded as a complication only if it results in clinical consequences such as a drop in the hemoglobin level, the need for blood transfusions, or clinical signs of recurrent bleeding after the endoscopic procedure.

Perforation has been reported with an estimated incidence <1 to 5 percent [70,81,82]. The risk is increased during piecemeal resection [82].

Strictures have been reported in 2 to 88 percent of patients undergoing ER for BE [68,77,79-81,84,85]. The size/length of the mucosal defect and the degree of circumferential involvement by the BE predict stricture formation [80,84,86]. In a study of 73 patients who underwent ER for BE with high-grade dysplasia or intramucosal carcinoma, symptomatic strictures developed in 25 percent. Strictures were more common if the BE involved more than 50 percent of the esophageal circumference (odds ratio [OR] 4.2, 95% CI 1.3-14). There was a trend toward tobacco use also increasing the risk (OR 3.3, 95% CI 0.93-12). Strictures arising after ER usually resolve with dilation [84].

INFORMATION FOR PATIENTS — UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)

Basics topics (see "Patient education: Barrett's esophagus (The Basics)")

Beyond the Basics topics (see "Patient education: Barrett's esophagus (Beyond the Basics)")


In patients with high-grade dysplasia (HGD) or early mucosal cancer complicating Barrett's esophagus (BE), we suggest endoscopic resection (ER) rather than surgery or ablative therapy, provided an experienced endoscopy is available and if the endoscopic appearance of the lesion does not raise suspicion for deep submucosal infiltration. ER should only be performed by trained endoscopists with experience in screening, imaging, and treatment of patients with early Barrett's neoplasia (Grade 2C). (See 'Evaluation for eligibility' above and 'Learning curve' above.)

ER is particularly useful in patients with nodular lesions.

ER aids in histopathologic diagnosis since it permits assessment of depth of infiltration and estimation of the risk for local lymph node metastasis. However, histopathologic interpretation of ER specimens may not be straightforward. (See 'Endoscopic resection as staging procedure' above and 'Pathologic assessment' above.)

Patients with HGD or early cancer should be referred to specialized centers that have integrated expertise in gastrointestinal endoscopy, imaging, surgery, and histopathology.

Patients treated with ER require regular follow-up to detect recurrent lesions. In most studies, patients are followed every three months during the first year and annually thereafter. (See 'Efficacy' above.)

Optimal techniques for performing ER alone or in conjunction with other endoscopic approaches are evolving. Combined with radiofrequency ablation, excellent eradication rates have been reported. Stepwise radical ER is associated with a higher rate of stenosis, and its use should be limited to patients with more extensive lesions. (See 'Endoscopic resection as part of endoscopic therapy' above.)

The most common complications from ER are bleeding and esophageal stricture formation, both of which can generally be addressed endoscopically. (See 'Complications' above.)

Use of UpToDate is subject to the  Subscription and License Agreement.


  1. Fernando HC, Luketich JD, Buenaventura PO, et al. Outcomes of minimally invasive esophagectomy (MIE) for high-grade dysplasia of the esophagus. Eur J Cardiothorac Surg 2002; 22:1.
  2. Nigro JJ, Hagen JA, DeMeester TR, et al. Occult esophageal adenocarcinoma: extent of disease and implications for effective therapy. Ann Surg 1999; 230:433.
  3. Nigro JJ, Hagen JA, DeMeester TR, et al. Prevalence and location of nodal metastases in distal esophageal adenocarcinoma confined to the wall: implications for therapy. J Thorac Cardiovasc Surg 1999; 117:16.
  4. Peters JH, Clark GW, Ireland AP, et al. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg 1994; 108:813.
  5. Rice TW, Blackstone EH, Goldblum JR, et al. Superficial adenocarcinoma of the esophagus. J Thorac Cardiovasc Surg 2001; 122:1077.
  6. Ruol A, Merigliano S, Baldan N, et al. Prevalence, management and outcome of early adenocarcinoma (pT1) of the esophago-gastric junction. Comparison between early cancer in Barrett's esophagus (type I) and early cancer of the cardia (type II). Dis Esophagus 1997; 10:190.
  7. Stein HJ, Feith M, Mueller J, et al. Limited resection for early adenocarcinoma in Barrett's esophagus. Ann Surg 2000; 232:733.
  8. van Sandick JW, Baak JP, van Lanschot JJ, et al. Computerized quantitative pathology for the grading of dysplasia in surveillance biopsies of Barrett's oesophagus. J Pathol 2000; 190:177.
  9. Ell C, May A, Gossner L, et al. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology 2000; 118:670.
  10. Nijhawan PK, Wang KK. Endoscopic mucosal resection for lesions with endoscopic features suggestive of malignancy and high-grade dysplasia within Barrett's esophagus. Gastrointest Endosc 2000; 52:328.
  11. Vieth M, Ell C, Gossner L, et al. Histological analysis of endoscopic resection specimens from 326 patients with Barrett's esophagus and early neoplasia. Endoscopy 2004; 36:776.
  12. Pech O, Behrens A, May A, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut 2008; 57:1200.
  13. Bennett C, Vakil N, Bergman J, et al. Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology 2012; 143:336.
  14. Schlemper RJ, Riddell RH, Kato Y, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000; 47:251.
  15. Skacel M, Petras RE, Gramlich TL, et al. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am J Gastroenterol 2000; 95:3383.
  16. Hulscher JB, Haringsma J, Benraadt J, et al. Comprehensive Cancer Centre Amsterdam Barrett Advisory Committee: first results. Neth J Med 2001; 58:3.
  17. Schnell TG, Sontag SJ, Chejfec G, et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001; 120:1607.
  18. Kara MA, Peters FP, Rosmolen WD, et al. High-resolution endoscopy plus chromoendoscopy or narrow-band imaging in Barrett's esophagus: a prospective randomized crossover study. Endoscopy 2005; 37:929.
  19. Kara MA, Smits ME, Rosmolen WD, et al. A randomized crossover study comparing light-induced fluorescence endoscopy with standard videoendoscopy for the detection of early neoplasia in Barrett's esophagus. Gastrointest Endosc 2005; 61:671.
  20. Curvers WL, Singh R, Song LM, et al. Endoscopic tri-modal imaging for detection of early neoplasia in Barrett's oesophagus: a multi-centre feasibility study using high-resolution endoscopy, autofluorescence imaging and narrow band imaging incorporated in one endoscopy system. Gut 2008; 57:167.
  21. Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology 2006; 131:1392.
  22. Pech O, Gossner L, Manner H, et al. Prospective evaluation of the macroscopic types and location of early Barrett's neoplasia in 380 lesions. Endoscopy 2007; 39:588.
  23. Reid BJ, Blount PL, Feng Z, Levine DS. Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia. Am J Gastroenterol 2000; 95:3089.
  24. Curvers WL, Bergman JJ. Multimodality imaging in Barrett's esophagus: looking longer, seeing better, and recognizing more. Gastroenterology 2008; 135:297.
  25. ASGE Standards of Practice Committee, Evans JA, Early DS, et al. The role of endoscopy in the assessment and treatment of esophageal cancer. Gastrointest Endosc 2013; 77:328.
  26. Larghi A, Lightdale CJ, Memeo L, et al. EUS followed by EMR for staging of high-grade dysplasia and early cancer in Barrett's esophagus. Gastrointest Endosc 2005; 62:16.
  27. Mino-Kenudson M, Hull MJ, Brown I, et al. EMR for Barrett's esophagus-related superficial neoplasms offers better diagnostic reproducibility than mucosal biopsy. Gastrointest Endosc 2007; 66:660.
  28. Peters FP, Brakenhoff KP, Curvers WL, et al. Histologic evaluation of resection specimens obtained at 293 endoscopic resections in Barrett's esophagus. Gastrointest Endosc 2008; 67:604.
  29. Buskens CJ, Westerterp M, Lagarde SM, et al. Prediction of appropriateness of local endoscopic treatment for high-grade dysplasia and early adenocarcinoma by EUS and histopathologic features. Gastrointest Endosc 2004; 60:703.
  30. Bergman JJ, Fockens P. Endoscopic ultrasonography in patients with gastro-esophageal cancer. Eur J Ultrasound 1999; 10:127.
  31. Fockens P, Van den Brande JH, van Dullemen HM, et al. Endosonographic T-staging of esophageal carcinoma: a learning curve. Gastrointest Endosc 1996; 44:58.
  32. May A, Günter E, Roth F, et al. Accuracy of staging in early oesophageal cancer using high resolution endoscopy and high resolution endosonography: a comparative, prospective, and blinded trial. Gut 2004; 53:634.
  33. Heeren PA, van Westreenen HL, Geersing GJ, et al. Influence of tumor characteristics on the accuracy of endoscopic ultrasonography in staging cancer of the esophagus and esophagogastric junction. Endoscopy 2004; 36:966.
  34. Pouw RE, Heldoorn N, Alvarez Herrero L, et al. Do we still need EUS in the workup of patients with early esophageal neoplasia? A retrospective analysis of 131 cases. Gastrointest Endosc 2011; 73:662.
  35. Inoue H, Fukami N, Yoshida T, Kudo SE. Endoscopic mucosal resection for esophageal and gastric cancers. J Gastroenterol Hepatol 2002; 17:382.
  36. Alvarez Herrero L, Pouw RE, van Vilsteren FG, et al. Safety and efficacy of multiband mucosectomy in 1060 resections in Barrett's esophagus. Endoscopy 2011; 43:177.
  37. Peters FP, Kara MA, Curvers WL, et al. Multiband mucosectomy for endoscopic resection of Barrett's esophagus: feasibility study with matched historical controls. Eur J Gastroenterol Hepatol 2007; 19:311.
  38. Pouw RE, van Vilsteren FG, Peters FP, et al. Randomized trial on endoscopic resection-cap versus multiband mucosectomy for piecemeal endoscopic resection of early Barrett's neoplasia. Gastrointest Endosc 2011; 74:35.
  39. Yamamoto H, Sekine Y, Higashizawa T, et al. Successful en bloc resection of a large superficial gastric cancer by using sodium hyaluronate and electrocautery incision forceps. Gastrointest Endosc 2001; 54:629.
  40. Miyamoto S, Muto M, Hamamoto Y, et al. A new technique for endoscopic mucosal resection with an insulated-tip electrosurgical knife improves the completeness of resection of intramucosal gastric neoplasms. Gastrointest Endosc 2002; 55:576.
  41. Ohkuwa M, Hosokawa K, Boku N, et al. New endoscopic treatment for intramucosal gastric tumors using an insulated-tip diathermic knife. Endoscopy 2001; 33:221.
  42. Hirasawa K, Kokawa A, Oka H, et al. Superficial adenocarcinoma of the esophagogastric junction: long-term results of endoscopic submucosal dissection. Gastrointest Endosc 2010; 72:960.
  43. Chevaux JB, Piessevaux H, Jouret-Mourin A, et al. Clinical outcome in patients treated with endoscopic submucosal dissection for superficial Barrett's neoplasia. Endoscopy 2015; 47:103.
  44. Terheggen G, Horn EM, Vieth M, et al. A randomised trial of endoscopic submucosal dissection versus endoscopic mucosal resection for early Barrett's neoplasia. Gut 2017; 66:783.
  45. Pimentel-Nunes P, Dinis-Ribeiro M, Ponchon T, et al. Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2015; 47:829.
  46. Kashin SV, Kuvaev R, Nadezhin AS, et al.. The new hybrid argon plasma coagulation (hybrid APC) for endoscopic ablation of Barrett's esohagus (BE): the results of the pilot trial. Gastrointest Endosc 2016; 83:AB495.
  47. Manner H, May A, Kouti I, et al. Efficacy and safety of Hybrid-APC for the ablation of Barrett's esophagus. Surg Endosc 2016; 30:1364.
  48. Choi IJ, Kim CG, Chang HJ, et al. The learning curve for EMR with circumferential mucosal incision in treating intramucosal gastric neoplasm. Gastrointest Endosc 2005; 62:860.
  49. Ohyama T, Kobayashi Y, Mori K, et al. Factors affecting complete resection of gastric tumors by the endoscopic mucosal resection procedure. J Gastroenterol Hepatol 2002; 17:844.
  50. Deprez PH, Bergman JJ, Meisner S, et al. Current practice with endoscopic submucosal dissection in Europe: position statement from a panel of experts. Endoscopy 2010; 42:853.
  51. van Vilsteren FG, Pouw RE, Herrero LA, et al. Learning to perform endoscopic resection of esophageal neoplasia is associated with significant complications even within a structured training program. Endoscopy 2012; 44:4.
  52. Takubo K, Sasajima K, Yamashita K, et al. Double muscularis mucosae in Barrett's esophagus. Hum Pathol 1991; 22:1158.
  53. Prasad GA, Buttar NS, Wongkeesong LM, et al. Significance of neoplastic involvement of margins obtained by endoscopic mucosal resection in Barrett's esophagus. Am J Gastroenterol 2007; 102:2380.
  54. Ormsby AH, Petras RE, Henricks WH, et al. Observer variation in the diagnosis of superficial oesophageal adenocarcinoma. Gut 2002; 51:671.
  55. Rice TW, Kelsen D, Blackstone EH, et al.. Esophagus and esophagogastric junction.. In: AJCC Cancer Staging Manual, 8th, Amin MB. (Ed), AJCC, Chicago 2017. p.185.
  56. American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.103.
  57. Manner H, May A, Pech O, et al. Early Barrett's carcinoma with "low-risk" submucosal invasion: long-term results of endoscopic resection with a curative intent. Am J Gastroenterol 2008; 103:2589.
  58. Alvarez Herrero L, Pouw RE, van Vilsteren FG, et al. Risk of lymph node metastasis associated with deeper invasion by early adenocarcinoma of the esophagus and cardia: study based on endoscopic resection specimens. Endoscopy 2010; 42:1030.
  59. Ciocirlan M, Lapalus MG, Hervieu V, et al. Endoscopic mucosal resection for squamous premalignant and early malignant lesions of the esophagus. Endoscopy 2007; 39:24.
  60. Esaki M, Matsumoto T, Hirakawa K, et al. Risk factors for local recurrence of superficial esophageal cancer after treatment by endoscopic mucosal resection. Endoscopy 2007; 39:41.
  61. May A, Gossner L, Pech O, et al. Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett's oesophagus: acute-phase and intermediate results of a new treatment approach. Eur J Gastroenterol Hepatol 2002; 14:1085.
  62. Ell C, May A, Pech O, et al. Curative endoscopic resection of early esophageal adenocarcinomas (Barrett's cancer). Gastrointest Endosc 2007; 65:3.
  63. Prasad GA, Wu TT, Wigle DA, et al. Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett's esophagus. Gastroenterology 2009; 137:815.
  64. Chennat J, Konda VJ, Ross AS, et al. Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma--an American single-center experience. Am J Gastroenterol 2009; 104:2684.
  65. Moss A, Bourke MJ, Hourigan LF, et al. Endoscopic resection for Barrett's high-grade dysplasia and early esophageal adenocarcinoma: an essential staging procedure with long-term therapeutic benefit. Am J Gastroenterol 2010; 105:1276.
  66. Pech O, Bollschweiler E, Manner H, et al. Comparison between endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrett's esophagus at two high-volume centers. Ann Surg 2011; 254:67.
  67. Wu J, Pan YM, Wang TT, et al. Endotherapy versus surgery for early neoplasia in Barrett's esophagus: a meta-analysis. Gastrointest Endosc 2014; 79:233.
  68. Chung A, Bourke MJ, Hourigan LF, et al. Complete Barrett's excision by stepwise endoscopic resection in short-segment disease: long term outcomes and predictors of stricture. Endoscopy 2011; 43:1025.
  69. Yamada M, Oda I, Nonaka S, et al. Long-term outcome of endoscopic resection of superficial adenocarcinoma of the esophagogastric junction. Endoscopy 2013; 45:992.
  70. Pech O, May A, Manner H, et al. Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. Gastroenterology 2014; 146:652.
  71. Konda VJ, Gonzalez Haba Ruiz M, Koons A, et al. Complete endoscopic mucosal resection is effective and durable treatment for Barrett's-associated neoplasia. Clin Gastroenterol Hepatol 2014; 12:2002.
  72. Leggett CL, Lewis JT, Wu TT, et al. Clinical and histologic determinants of mortality for patients with Barrett's esophagus-related T1 esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2015; 13:658.
  73. Chadwick G, Groene O, Markar SR, et al. Systematic review comparing radiofrequency ablation and complete endoscopic resection in treating dysplastic Barrett's esophagus: a critical assessment of histologic outcomes and adverse events. Gastrointest Endosc 2014; 79:718.
  74. Manner H, Rabenstein T, Pech O, et al. Ablation of residual Barrett's epithelium after endoscopic resection: a randomized long-term follow-up study of argon plasma coagulation vs. surveillance (APE study). Endoscopy 2014; 46:6.
  75. Phoa KN, Pouw RE, van Vilsteren FG, et al. Remission of Barrett's esophagus with early neoplasia 5 years after radiofrequency ablation with endoscopic resection: a Netherlands cohort study. Gastroenterology 2013; 145:96.
  76. Seewald S, Akaraviputh T, Seitz U, et al. Circumferential EMR and complete removal of Barrett's epithelium: a new approach to management of Barrett's esophagus containing high-grade intraepithelial neoplasia and intramucosal carcinoma. Gastrointest Endosc 2003; 57:854.
  77. Pouw RE, Seewald S, Gondrie JJ, et al. Stepwise radical endoscopic resection for eradication of Barrett's oesophagus with early neoplasia in a cohort of 169 patients. Gut 2010; 59:1169.
  78. Desai M, Saligram S, Gupta N, et al. Efficacy and safety outcomes of multimodal endoscopic eradication therapy in Barrett's esophagus-related neoplasia: a systematic review and pooled analysis. Gastrointest Endosc 2017; 85:482.
  79. van Vilsteren FG, Pouw RE, Seewald S, et al. Stepwise radical endoscopic resection versus radiofrequency ablation for Barrett's oesophagus with high-grade dysplasia or early cancer: a multicentre randomised trial. Gut 2011; 60:765.
  80. Lewis JJ, Rubenstein JH, Singal AG, et al. Factors associated with esophageal stricture formation after endoscopic mucosal resection for neoplastic Barrett's esophagus. Gastrointest Endosc 2011; 74:753.
  81. Gerke H, Siddiqui J, Nasr I, et al. Efficacy and safety of EMR to completely remove Barrett's esophagus: experience in 41 patients. Gastrointest Endosc 2011; 74:761.
  82. Soetikno RM, Gotoda T, Nakanishi Y, Soehendra N. Endoscopic mucosal resection. Gastrointest Endosc 2003; 57:567.
  83. Peters FP, Kara MA, Rosmolen WD, et al. Endoscopic treatment of high-grade dysplasia and early stage cancer in Barrett's esophagus. Gastrointest Endosc 2005; 61:506.
  84. Katada C, Muto M, Manabe T, et al. Esophageal stenosis after endoscopic mucosal resection of superficial esophageal lesions. Gastrointest Endosc 2003; 57:165.
  85. Larghi A, Lightdale CJ, Ross AS, et al. Long-term follow-up of complete Barrett's eradication endoscopic mucosal resection (CBE-EMR) for the treatment of high grade dysplasia and intramucosal carcinoma. Endoscopy 2007; 39:1086.
  86. Qumseya B, Panossian AM, Rizk C, et al. Predictors of esophageal stricture formation post endoscopic mucosal resection. Clin Endosc 2014; 47:155.
Topic 2651 Version 27.0

Topic Outline



All topics are updated as new information becomes available. Our peer review process typically takes one to six weeks depending on the issue.